Clostridium difficile infection: current state of the problem


Citar

Texto integral

Resumo

The present article is concerned with modern aspects of infection caused by Clostridium difficile. The main forms of its course are antibiotic-associated diarrhea and pseudomembranous colitis. Risk factors for infection C. difficile, its clinical manifestations, and diagnostic and treatment issues are considered in detail. It is stated that drugs of choice in the treatment of infections C. difficile are metronidazole and vancomycin. It is emphasized that the uncontrolled use of antibacterial drugs contributes the growth of infection C. difficile.

Sobre autores

V Malov

V Malov

Bibliografia

  1. Лобзин Ю.В., Волжанин В.М., Захаренко С.М. Проблема инфекции в современной клинической медицине // Врач. 2004. № 2. С. 5-9.
  2. Knoop FC, Owens M, Crocker IC. Clostridium difficile: Clinical Disease and Diagnosis. Clin Microbiol Rev 1993;6:251-65.
  3. Малов В.А., Бондаренко В.М., Пак С.Г. Роль Clostridium difficile в патологии человека // Журнал микробиологии. 1996. № 1. С. 91-96.
  4. Малов В.А. Антибиотикоассоциированные диареи // Клиническая микробиология и антимикробная химиотерапия.2002. № 1. С. 22-32.
  5. Лобзин Ю.В., Захаренко С.М., Иванов Г.А. Современные представления об инфекции Clostridium difficile // Клиническая микробиология и антимикробная терапия. 2002. № 3. С. 200-32.
  6. Hummel RP, Altemeier WA, Hill EO. Iatrogenic staphylococcal enterocolitis. Ann Surg 1964;160:551-60.
  7. Thielman NM. Antibiotic-associated colitis. In: Mandell G.L., Bennett J.E., Dolin R. eds. Principles and practice of infectious diseases. 5th ed. Philadelphia, 2000, v.1, p. 1111-1126.
  8. Tedesco FJ, Barton RW, Alpers DH. Clindamycin-associated colitis. Ann Intern Med 1974;81:429-33.
  9. Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006;12(6):2-18.
  10. Barbut F, Mastrantonio P, Delmée M, et al. Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect 2007;13:1048-57.
  11. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004;171:466-72.
  12. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998;40:1-15.
  13. Bartlett JG. Clinical practice: antibiotic-associated diarrhea. N Engl J Med 2002;346:334-9.
  14. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254-60.
  15. McFarland LV, Mulligan ME, Kwok RY, et al. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989;320:204-10.
  16. Simor AE, Bradley SF, Strausbaugh LJ, et al. Clostridium difficile in long-term-care facilities for the elderly. Infect Control Hosp Epidemiol 2002;23:696-703.
  17. Chang VT, Nelson K. The role of physical proximity in nosocomial diarrhea. Clin Infect Dis 2000;31:717-22.
  18. Aronsson B, Mollby R, Nord CE. Diagnosis and epidemiology of Clostridium difficile enterocolitis in Sweden. J Antimicrob Chemother 1984;14:85-95.
  19. Karlstrom O, Fryklund B, Tullus K, Burman LG. A prospective nationwide study of Clostridium difficile-associated diarrhea in Sweden. The Swedish C. difficile Study Group. Clin Infect Dis 1998;26:141-5.
  20. Viscidi R, Willey S, Bartlett JG. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology 1981;81:5-9.
  21. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998;40:1-15.
  22. Siegel DL, Edelstein PH, Nachamkin I. Inappropriate testing for diarrheal diseases in the hospital. JAMA 1990;263:979-82.
  23. Hogenauer C, Hammer HF, Krejs GJ, et al. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis 1998;27:702-10.
  24. Hogenauer C, Langner C, Beubler E, et al. Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. N Engl J Med 2006;355:2418-26.
  25. Young VB, Schmidt TM. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J Clin Microbiol 2004;42:1203-6.
  26. Bartlett JG. Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin Infect Dis 1994;8(4):265-72.
  27. Bhargava A, Sen P, Swaminathan A, et al. Rapidly Progressive Necrotizing Fasciitis and Gangrene Due to Clostridium difficile: Case Report. Clin Infect Dis 2000;30:954-5.
  28. Byl B, Jacobs F. Extraintestinal Clostridium difficile infections. Clin Infect Dis 1996;22:712.
  29. Bartlett JG, Taylor NS, Chang T, et al. Clinical and laboratory observations in Clostridium difficile colitis. Am J Clin Nutr 1980;33(11):2521-26.
  30. Olson MM, Shanholtzer CJ, Lee JT, et al. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol 1994;15:371-81.
  31. O'Connor D, Hynes P, Cormican M, et al. Evaluation of methods for detection of toxins in specimens of feces submitted for diagnosis of Clostridium difficile - associated diarrhea. J Clin. Microbiol. 2001;39:2846-49.
  32. Ticehurst J.R, Aird DZ, Dam LM, et al. Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol 2006;44:1145-9.
  33. Kawamoto S, Horton KM, Fishman EK. Pseudomembranous colitis: spectrum of imaging findings with clinical and pathologic correlation. Radiographics 1999;19:887-97.
  34. Zar FA, Bakkanagari SR, Moorthi K, et al. A Comparison of Vancomycin and Metronidazole for the Treatment of Clostridium difficile-Associated Diarrhea, Stratified by Disease Severity. Clin Infect Dis 2007;45:302-7.
  35. Goldin BR, Gorbach SL. Clinical Indications for Probiotics: An Overview. Clin Infect Dis 2008;46(2):96-100.
  36. Информационное сообщение // Фарматека. 2008. № 5. С. 9.
  37. http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2539&mid=1085056570&magid=188

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies